Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    cp12-0919
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo;   Biological: Ramucirumab DP (IMC-1121B);   Other: BSC

Study has passed its completion date and status has not been verified in more than two years.